Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Healthy Subjects
NCT07478133Completed
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nalfurafine in pruritus (2 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Peak Plasma Concentration at 36 hours, Area under the plasma concentration versus time curve from time 0 to t at 36 hours and 1 more. Started May 2023; status: completed.
02
Drugs
nalfurafine
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT07478133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478133.